Advisory Committee Unanimously Rejects Sanofi’s Zimulti
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously votes against approval of Sanofi-Aventis’ rimonabant for a weight loss indication.
You may also be interested in...
GW Succeeding With Cannabinoid Drug This Time Around
Drug candidates targeting the cannabinoid receptors have a spotty past, so GW's successful Phase III data in pediatric epilepsy meets with great investor enthusiasm.
Eric Colman, FDA’s Lead Obesity Drug Reviewer, Dies At Age 53
As a reviewer, team leader and deputy director in the Division of Metabolism and Endocrinology Products, Colman spearheaded the agency’s policy development on weight-management products.
UK’s NICE Proposes Coverage For Troubled Sanofi Obesity Drug Rimonabant
British agency recommends CB-1 receptor antagonist as adjunct to diet and exercise for obese adults intolerant of Xenical, Meridia.